Cancer
FDA approves Regeneron & Sanofi’s Libtayo for advanced non-small cell lung cancer
February 23, 2021Manufacturing and Production Cancer, Sanofi
The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …
ONK and Anthony Nolan combine forces to work on blood cancer therapies
February 22, 2021Sales and Marketing Anthony Nolan, Cancer, ONK, blood cancer, cancer treatment
ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) …
MaxiVAX and Minaris sign manufacturing deal for cell-based cancer immunotherapy
February 22, 2021Sales and Marketing Cancer, MaxiVAX, Minaris
MaxiVAX and Minaris Regenerative Medicine have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of …
Seagen’s breast cancer drug TUKYSA gets UK approval
February 22, 2021Sales and Marketing Cancer, MHRA, Seagen
The MHRA has granted marketing authorisation in the UK for Seagen’s TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, for …
New Cell Guidance technology has potential to help treat cancer
February 19, 2021Medical Communications Cancer, cancer treatment, cell guidance systems, macrophages, pharma news
Cell Guidance Systems’ new POlyhedrin Delivery System (PODS) technology has been shown to have therapeutic potential in the treatment of …
Nektar and SFJ collaborate to develop experimental head and neck cancer drug
February 18, 2021Cancer, Nektar Therapeutics
Nektar Therapeutics has announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG), an investigational CD122-preferential …
AstraZeneca and MSD’s Lynparza crosses superiority boundary for invasive disease-free survival
February 17, 2021Research and Development AstraZeneca, Cancer, MSD
The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …
Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu approved in UK
February 16, 2021Manufacturing and Production AstraZeneca, Cancer, Daiichi Sankyo
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted conditional authorisation in the UK as a monotherapy for the …
FDA approves Sanofi’s Libtayo for advanced basal cell carcinoma
February 10, 2021Research and Development Cancer, FDA, Sanofi
The FDA has approved Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell …
Janssen announces positive Phase III results for prostate cancer drug apalutamide
February 10, 2021Research and Development Cancer, Janssen
Final results from Janssen’s Phase III TITAN study have shown its cancer drug apalutamide improved overall survival (OS) in patients …
Merck, Pfizer, and 4D pharma join forces for bladder cancer clinical trial
February 8, 2021Sales and Marketing Cancer, Merck, Pfizer
A clinical trial collaboration between 4D pharma, Merck, and Pfizer to treat locally advanced or metastatic urothelial carcinoma (UC), also …
Researchers make neuroblastoma drug target discovery
February 8, 2021Sales and Marketing Cancer, GOSH, neuroblastoma
Scientists conducting the largest single cell study to date of the childhood cancer neuroblastoma have made a breakthrough in identifying …
AstraZeneca’s Imfinzi misses target in Phase III head and neck cancer trial
February 5, 2021Medical Communications AstraZeneca, Cancer
AstraZeneca’s Imfinzi (durvalumab) has failed to improve overall survival (OS) for patients with recurrent or metastatic head and neck cancer …
NICE recommends MSD’s Keytruda in combination with chemotherapy for lung cancer
February 4, 2021Cancer, MSD
NICE has recommended MSD’s Keytruda (pembrolizumab) with pemetrexed and platinum chemotherapy (pembrolizumab combination) as a first-line option for untreated, metastatic, …
New urine test could detect womb cancer in three hours
February 3, 2021Research and Development Cancer, urine test
A simple test using patented technology to detect the cancer biomarker MCM5 (Minichromosome Maintenance Complex Component 5) in urine could …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
